Tissue Aortic Valve Replacement Research Articles

Sub-coronary aortic root replacement post-aortic valve dehiscence: a case report

This is a case report of a 78-year-old male who underwent a sub-coronary aortic valve and root replacement due to valve dehiscence and aortic root pseudoaneurysm. The patient had complex anomalous coronary anatomy and had undergone a previous tissue aortic valve replacement in 2013. The patient made an uneventful recovery and was discharged from the hospital five days later. The authors suggest that the sub-coronary root replacement technique should be considered in elderly patients and patients with complex coronary anatomy.

Budget impact analysis of a bioprosthetic valve with a novel tissue versus mechanical aortic valve replacement in patients older than 65 years with aortic stenosis in Saudi Arabia

Aims A budget impact analysis (BIA) comparing bioprosthetic valves with RESILIA tissue and mechanical valves in aortic stenosis (AS) patients > 65 years in the public and private sectors of Saudi Arabia. Materials and methods A decision-tree with a partitioned survival model was adapted to estimate the financial consequences of either a RESILIA tissue valve or a mechanical valve in aortic valve replacement (AVR) procedures up to 5 years. The budget impact of resource consumption for both valve types was compared and included disabling strokes, reoperations, minor thromboembolic events, major bleeding, endocarditis, anticoagulation treatment and monitoring, and echocardiogram assessments. One-way sensitivity analyses (OWSA) were performed on cost and probability inputs. Results RESILIA tissue valves versus mechanical valves are overall budget saving commencing in Year 1 and savings gradually increase year-on-year. The higher costs of the initial procedure, reoperation, and additional monitoring (echocardiogram tests and visits) associated with RESILIA tissue valves are offset by savings in warfarin use, disabling strokes, major bleeding, and anticoagulation complications. The cost per initial procedure per patient is SAR795 higher for a RESILIA tissue valve reflecting the higher valve acquisition cost, which is partially offset by a shorter hospital stay. The OWSA suggests that total procedure costs of each valve, including the hospital stay, are the main cost drivers in the model. Limitations The variability of cost inputs and the presence of multiple payers with multiple costing data is a key challenge in Saudi Arabia. Budget impact results may, therefore, change if repeated per AVR center and may also be impacted by the long-term durability of RESILIA tissue valves. Conclusions An AVR in patients > 65 years with a RESILIA tissue valve is budget-saving from the first year in Saudi Arabia. Patients, payers, providers and policymakers may benefit economically from increased implantation of RESILIA tissue valves.

Long-term Outcomes of Concomitant Surgical Ablation for Atrial Fibrillation

BackgroundThe long-term outcomes of surgical ablation for atrial fibrillation (AF) during cardiac surgery remain unclear. MethodsThis nationwide population-based retrospective cohort study used data from Taiwan’s National Health Insurance Research Database. Overall, 11,459 patients undergoing coronary artery bypass graft, valve, or aortic surgery and diagnosed as having AF between January 1, 2001, and December 31, 2016, were included. To reduce possible selection bias, we created a propensity score–matched cohort and compared outcomes between groups. The outcomes of interest were long-term survival and late ischemic stroke. ResultsThe surgical ablation group had a significantly lower risk of all-cause mortality (5.74 and 7.69 events per 100 patient-years, respectively; hazard ratio, 0.75; 95% CI, 0.69-0.81) and ischemic stroke after discharge (1.88 and 2.52 events per 100 patient-years, respectively; subdistribution hazard ratio, 0.78; 95% CI, 0.67-0.91). AF ablation performed concomitantly with coronary artery bypass graft surgery, tissue aortic valve replacement, tissue mitral valve replacement, or mitral valve repair led to significantly better long-term survival (P = .0176, P = .0001, P < .0001, P < .0001, respectively). The surgical ablation group also had better long-term survival than the matched general AF population (log-rank test, P < .001). ConclusionsConcomitant AF ablation during cardiac surgery is safe, does not increase the rate of perioperative complications, and confers the benefit of long-term survival after cardiac surgery in adults. AF ablation also improved cardiac surgery patients’ long-term survival compared with the matched general AF population.

Autoimmune connective tissue diseases and aortic valve replacement outcomes: a population-based study.

AimsPatients with autoimmune connective tissue diseases (CTDs) have a high burden of valvular heart disease and are often thought of as high surgical risk patients.Methods and resultsPatients undergoing aortic valve replacement (AVR) were identified in the Nationwide Readmissions Database between January 2012 and December 2018. Patients with a history of systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, mixed C, Sjögren syndrome, polymyositis, and dermatomyositis were included in the CTD cohort. Patients undergoing coronary artery bypass grafting concomitantly with AVR were excluded. A total of 569 600 hospitalizations were included, of which16 531 (2.9%) had CTD. CTD patients were more likely to be females, with higher rates of heart failure, pulmonary hypertension, and more likely to be insured by Medicare. CTD patients had lower mortality than non-CTD patients [odds ratio (OR) 0.66; 95% confidence interval (CI): 0.59–0.74] and stroke [OR 0.87; 95% (CI): 0.79–0.97]. CTD patients undergoing SAVR had lower mortality [OR 0.69; 95% (CI): 0.60–0.80] and stroke [OR 0.86; 95% (CI): 0.75–0.98). CTD patients undergoing TAVR had lower mortality outcomes [OR 0.67; 95% (CI): 0.56–0.80]; however, they had comparable stroke outcomes [OR 0.97; 95% (CI): 0.83–1.13, P = 0.69].ConclusionsOutcomes for patients with CTD requiring AVR are not inferior to their non-CTD counterparts. A comprehensive heart team selection of patients undergoing AVR approaches should place CTD history under consideration; however, pre-existing CTD should not be prohibitive of AVR interventions.

Tissue aortic valve replacement: expectations and reality.

Tissue aortic valve replacement: expectations and reality.

Abstract 17057: Tropheryma Whipplei Endocarditis: A Diagnosis In Hindsight

Description of case: We report a case of Tropheryma whipplei endocarditis, a rare cause of blood-culture-negative infective endocarditis (BCNIE). Due to its rarity and lack of availability of diagnostic tests in district hospitals, the diagnosis remains challenging. The objective of this case report is to increase physician awareness of this pathogen. A 61-year-old man presented to the Emergency Department with central chest pain at rest. A 12-lead ECG demonstrated ST- segment depression in V4-V6 leads, and his serial troponin levels were raised. He was commenced on treatment for acute coronary syndrome and transferred to the Coronary Care Unit. An echocardiogram showed a 15mm x 15mm vegetation in the aortic valve with mild aortic regurgitation. His initial microbiology workup, which included two sets of blood cultures (pre-antibiotics), MRSA screen &amp; COVID-19 PCR, was negative. He was transferred to a cardiothoracic centre four days later. Pre-operative CT coronary angiogram showed severe three vessel coronary artery disease. He underwent triple coronary artery by-pass grafts and tissue aortic valve replacement. During early post-op recovery, he had fever episodes and an elevated C-reactive protein of 280 mg/L but normal white cell counts. He was treated with intravenous Tazocin for hospital-acquired pneumonia and discharged on doxycycline. Two weeks post-discharge, he had a positive 16S/18S PCR for Tropheryma whipplei on molecular analysis of the aortic valve. He was treated for Whipples endocarditis with a 4-week course of IV Ceftriaxone, followed by a 12-month course of oral Cotrimoxazole. The patient has reported doing well since the surgery. Discussion: Molecular assay with PCR of the heart valve is the mainstay of diagnosing Whipple’s endocarditis. There have been 5 previously reported cases of Whipple’s endocarditis in the United Kingdom in our knowledge. It is likely under-reported because of a reliance on tissue diagnosis. Preceding intestinal manifestations and arthralgia should raise its clinical suspicion for timely workup. Physician awareness of Whipple’s Endocarditis is paramount in investigating for this pathogen.

Assessing the methodology used to study the ascending aorta haemodynamics in bicuspid aortic valve.

Modern imaging techniques provide evermore-detailed anatomical and physiological information for use in computational fluid dynamics to predict the behaviour of physiological phenomena. Computer modelling can help plan suitable interventions. Our group used magnetic resonance imaging and computational fluid dynamics to study the haemodynamic variables in the ascending aorta in patients with bicuspid aortic valve before and after isolated tissue aortic valve replacement. Computer modelling requires turning a physiological model into a mathematical one, solvable by equations that undergo multiple iterations in four dimensions. Creating these models involves several steps with manual inputs, making the process prone to errors and limiting its inter- and intra-operator reproducibility. Despite these challenges, we created computational models for each patient to study ascending aorta blood flow before and after surgery. Magnetic resonance imaging provided the anatomical and velocity data required for the blood flow simulation. Patient-specific in- and outflow boundary conditions were used for the computational fluid dynamics analysis. Haemodynamic variables pertaining to blood flow pattern and derived from the magnetic resonance imaging data were calculated. However, we encountered problems in our multi-step methodology, most notably processing the flow data. This meant that other variables requiring computation with computational fluid dynamics could not be calculated. Creating a model for computational fluid dynamics analysis is as complex as the physiology under scrutiny. We discuss some of the difficulties associated with creating such models, along with suggestions for improvements in order to yield reliable and beneficial results.

Fusion of Bovine Tissue Aortic Valve Leaflets in a Patient with Left Ventricular Assist Device: A Case Report

<h3>Introduction</h3> We present a case of a patient with prior bioprosthetic aortic valve replacement who underwent Left Ventricular Assist Device (LVAD) explant and was found to have fused valve leaflets at the time of surgery. <h3>Case Report</h3> The patient is a 30 year old woman with a history of a congenital quadricuspid aortic valve (frequency < 0.05%), complicated by myocardial infarction and cardiogenic shock with LVEF 5% due to occlusion of the left main coronary ostium by rupture of one of the leaflets. She required support via Veno-Arterial ExtraCorporeal Membrane Oxygenation (VA-ECMO) followed by Aortic Valve Replacement with #23 Bovine Tissue Valve and HeartMate 3™ (Abbot Laboratories) implantation in January 2019. Her LVEF improved to 55% after 6 months of mechanical circulatory support. The patient was scheduled for LVAD explant 9 months after implant. Intraoperative transesophageal echocardiogram showed leaflet fibrosis & severe functional closure of her prosthetic aortic valve and left ventricular outflow tract, not seen on prior echocardiograms (Figure 1). We performed an LVAD explant via redo sternotomy and left anterolateral thoracotomy, redo-aortic valve replacement with a #19 mechanical valve, and ventriculotomy closure using custom made synthetic plug. She is doing well 13 months after surgery. <h3>Summary</h3> Patients with prior tissue aortic valve replacement require careful preoperative evaluation before LVAD explant. Though we had a good outcome, pre-procedural knowledge of valve dysfunction is critical in surgical planning. We have developed an algorithm which may be utilized in the future to improve outcomes (Figure 2).

Acute coronary syndrome caused by extrinsic coronary compression from an aortic root abscess in a patient with mechanical aortic valve endocarditis: a case report and literature review.

Background Extrinsic coronary compression is an extremely rare complication of aortic root abscess formation and can manifest as an acute coronary syndrome in infective endocarditis. Optimal management strategies are unknown and therefore illustrative case reports may be informative.Case summary We describe a 63-year-old man with a background history of a mechanical aortic valve who developed sepsis due to Escherichia coli bacteraemia from a presumed urinary source. He suddenly deteriorated with cardiogenic shock and anterior ST-segment elevation myocardial infarction on Day 16 and received emergency percutaneous coronary intervention for severe stenoses of left anterior descending and diagonal arteries. A transoesophageal echocardiogram 2 days later demonstrated a large aortic root abscess. He was transferred for emergency surgery which revealed a large aortic abscess surrounding the left main stem confirming extrinsic coronary compression. He received a redo tissue aortic valve replacement and repair of his abscess cavity.Discussion We describe a case where percutaneous coronary intervention and emergency surgery was used to treat extrinsic compression from an aortic root abscess; a complication that is associated with a high mortality. This is also a rare case of E. coli causing prosthetic valve endocarditis. We also explore the findings of 11 previous cases of extrinsic coronary compression from aortic root abscess.

Long-term Healthcare Expenditures Over Time for Tissue and Mechanical Aortic Valve Replacement

Guidelines currently indicate the use of surgical aortic valve replacement (SAVR) to treat severe cases of aortic stenosis, particularly for low- to medium-risk patients. Although several studies have compared health outcomes of tissue and mechanical SAVR, this economic simulation model estimates the difference in long-term healthcare costs associated with tissue relative to mechanical SAVR. The deterministic and Monte Carlo simulation models used literature-based epidemiologic and cost inputs to calculate annual expenditures related to SAVR for up to 25 years after initial surgery. A series of 3 cohort studies across different age groups provided the health outcome probabilities for tissue valve patients. Outcome probabilities for mechanical valve patients were based on relative risks reported in comparative meta-analyses or large cohort studies. Relative to mechanical SAVR the expected net discounted savings for a patient receiving tissue SAVR at ages 45, 55, and 65 years were $12,266, $15,462, and $16,008, respectively (based on 2018 US dollars) over a 25-year horizon (95% confidence intervals exceed $0). For a 45-year-old tissue SAVR patient, the estimated per-patient cost difference (relative to mechanical SAVR) of reoperation over 25 years ($16,201) were offset by expected savings on anticoagulation monitoring ($26,257) over the same period. In a sensitivity analysis in which mortality risk was assumed equal, significant long-term savings associated with tissue SAVR still accrued in each of the 3 age cohorts. Payers, providers, and the healthcare system may financially benefit from the use of tissue valves because significant savings were associated with the use of tissue valves relative to mechanical valves for SAVR.

Outcomes of tissue versus mechanical aortic valve replacement in patients 50 to 70 years of age.

Societal guidelines suggest that aortic valve replacement (AVR) in patients age 50 to 70 years can be performed with either bioprosthetic or mechanical valves. This study reviewed outcomes between these valve types among patients aged 50 to 70 years undergoing AVR. We examined adult patients 50 to 70 years undergoing isolated AVR with a mechanical or bioprosthetic valve at a single institution between 2010 and 2018. Kaplan-Meier analysis was used to evaluate longitudinal survival and multivariable Cox regression analysis was used for risk adjustment. A propensity-matched analysis was performed as well. A total of 723 patients underwent isolated AVR with 467 (64.6%) receiving a bioprosthetic valve. At baseline, patients undergoing bioprosthetic AVR were older (median 65 vs 60 years; P < .001). One-year survival was comparable, however, survival at 5 years was significantly higher among patients undergoing mechanical AVR (95.5% vs 82.6%; P = .010). Among the 196 matched pairs, bioprosthetic AVR was associated with an increased adjusted hazard for death (hazards ratio, 3.29; P < .001). Additionally, 5-year freedom from stroke and bleeding were similar following matching, though mechanical AVR was associated with a greater freedom from repeat valve intervention (97.5% vs 92.9%; P = .020). In patients age 50 to 70, mechanical AVR is associated with improved long-term survival and freedom from repeat aortic valve intervention. Further large cohort studies should be performed to explore the potential benefits of mechanical valve replacement in this age range.

Rapid deployment valves versus conventional tissue valves for aortic valve replacement

ObjectivesRapid deployment valves have been developed as a means to adjust for limitations in transcatheter aortic valve replacement and surgical aortic valve replacement for the management of aortic valve disease. To date, many studies have shown that although rapid deployment valves facilitate a shorter surgical aortic valve replacement, they offer no clinical benefit. The purpose of this study was to compare the outcomes of rapid deployment valves with conventional surgical aortic valve replacement. MethodsThis study was a retrospective review of all patients undergoing tissue aortic valve replacement at a single center. The majority of patients were men and aged more than 60 years. Patients were categorized into 2 groups: (1) rapid deployment valves and (2) conventional sutured valve. Inverse probability treatment weighting method was used to create a cohort of patients with similar baseline characteristics. Kaplan–Meier curves and log-rank tests were used to determine if there were statistically significant differences in outcomes. Primary outcome was all-cause mortality at 30 days, 1 year, and 5 years. ResultsA total of 2237 patients made up the study population from 2013 to 2019. After inverse probability treatment weighting, there were 295 patients in each group. Shorter cardiopulmonary bypass and crossclamp times were found with the rapid deployment valves. No statistically significant difference was found in the primary and secondary outcomes. There was a significant difference in the rate of permanent pacemaker insertion with a 7% pacemaker rate in the rapid deployment valve group (P < .009). ConclusionsThe data suggest that rapid deployment valves offer no benefit in straightforward aortic valve replacement, and further study will help identify which patient population the valve is suited for.

UTILITY OF TROPONIN I AND CARDIAC MAGNETIC RESONANCE IN THE ASSESSMENT OF CARDIAC INVOLVEMENT IN IDIOPATHYC INFLAMMATORY MYOSITIS

Cardiac troponins are established markers of myocardial injury, with Troponin I (cTnI) having higher specificity compared to Troponin T (TnT). An 80 year-old female with previous tissue aortic valve replacement (tAVR) and hypertension experienced a collapse in the context of generalised muscle

Optimal Anticoagulation After Tissue Aortic and Mitral Valve Replacement

Optimal Anticoagulation After Tissue Aortic and Mitral Valve Replacement

Aortic valve endocarditis with root abscess causing superior vena cava obstruction: a case report

BackgroundTo our knowledge, we report the first case of endocarditis with root abscess causing compressive superior vena cava (SVC) obstruction.Case summaryAn 84-year-old gentleman with previous tissue aortic valve replacement presented with fevers and systemic upset. Blood cultures grew Streptococcus anginosus and transoesophageal echocardiogram identified prosthetic valve vegetations with an associated root abscess. Antibiotics were commenced and referral made for surgical consideration. Several days into treatment the patient developed clinical signs of SVC obstruction and computed tomography demonstrated an enlarging root abscess with SVC compression. The patient was discussed with local cardiothoracic centres, but surgery was not an option primarily due to abscess size and vascular involvement. Priority moved from active to palliative treatment given no improvement with antibiotics, unsuitability for surgery, and patient discomfort. Within several weeks, symptoms/signs of SVC obstruction actually improved, likely due to collateral venous circulation formation and the patient was discharged home with palliative care input.DiscussionThere are previous reports of SVC obstruction related to infected SVC thrombus, indwelling intravascular devices, and para-aortic abscess, but none related to infective endocarditis. Streptococcus anginosus endocarditis is rare but often associated with abscess formation, and male gender, increasing age, and previous surgery are recognized risk factors.

Clinical and cost-effectiveness of the Ross procedure versus conventional aortic valve replacement in young adults

ObjectivesIn young and middle-aged adults, there are three current options for aortic valve replacement (AVR), namely mechanical AVR (mechAVR), tissue AVR (biological AVR) and the Ross operation, with no clear...

Tissue versus mechanical aortic valve replacement in younger patients: A multicenter analysis

ObjectiveThe goal of this study was to examine the long-term survival of patients between the ages of 50 and 65 years who underwent tissue versus mechanical aortic valve replacement (AVR) in a multicenter cohort. MethodsA multicenter, retrospective analysis of all AVR patients (n = 9388) from 1991 to 2015 among 7 medical centers reporting to a prospectively maintained clinical registry was conducted. Inclusion criteria were: patients aged 50 to 65 years who underwent isolated AVR. Baseline comorbidities were balanced using inverse probability weighting for a study cohort of 1449 AVRs: 840 tissue and 609 mechanical. The primary end point of the analysis was all-cause mortality. Secondary end points included in-hospital morbidity, 30-day mortality, length of stay, and risk of reoperation. ResultsDuring the study period, there was a significant shift from mechanical to tissue valves (P < .001). There was no significant difference in major in-hospital morbidity, mortality, or length of hospitalization. Also, there was no significant difference in adjusted 15-year survival between mechanical versus tissue valves (hazard ratio, 0.87; 95% confidence interval [CI], 0.67-1.13; P = .29), although tissue valves were associated with a higher risk of reoperation with a cumulative incidence of 19.1% (95% CI, 14.4%-24.3%) versus 3.0% (95% CI, 1.7%-4.9%) for mechanical valves. The reoperative 30-day mortality rate was 2.4% (n = 2) for the series. ConclusionsAmong patients 50 to 65 years old who underwent AVR, there was no difference in adjusted long-term survival according to prosthesis type, but tissue valves were associated with a higher risk of reoperation.

Aggressive tissue aortic valve replacement in younger patients and the risk of re-replacement: Implications from microsimulation analysis

ObjectiveAdvances in transcatheter aortic valve replacement have led to the consideration of tissue aortic valve replacement in younger patients. Part of this enthusiasm is the presumption that younger patients would have more flexibility in future treatment options, such as a primary surgical aortic valve replacement followed later by transcatheter aortic valve replacement(s) (valve-in-valve), vice versa, or other permutations. We created a microsimulation model using published longevity of tissue valves to predict the outcomes of patients after primary tissue surgical aortic valve replacement. MethodsThe model calculated survival by incorporating annual mortality (Social Security Administration) and mortality from re-replacements (Society of Thoracic Surgeons) in patients with surgical aortic valve replacement. Freedom from reoperation for structural valve degeneration incorporated best published data to determine the annual risk of re-replacement for structural valve degeneration based on implant duration and stratified by patient age. A constant rate of re-replacement for nonstructural valve degeneration indications was also incorporated. Each simulation was performed for 50,000 individuals. Kaplan–Meier curves were generated to represent survival. All simulations were run within the MATLAB environment (The MathWorks, Inc, Natick, Mass). ResultsEarlier decades of life at primary surgical aortic valve replacement were associated with higher incidences of re-replacements and especially multiple re-replacements. For those patients receiving a primary tissue surgical aortic valve replacement at age 50 years, 57.2% will require a second valve, 18.0% will require a third valve, and 1.6% will require a fourth valve with average operative mortalities of 2.9%, 4.8%, and 7.3%, respectively. A 50-year-old patient at primary surgical aortic valve replacement has a 13.1% chance of re-replacement before turning 60 years of age. ConclusionsMicrosimulation incorporates changing hazards to estimate the risk of aortic valve re-replacement in patients undergoing tissue surgical aortic valve replacement and may be a starting point for patient education and health care economic planning.

Campylobacter fetus prosthetic valve endocarditis presenting as a stroke

IntroductionCampylobacter is a common pathogen of the gastrointestinal tract, but invasive disease is rare. Campylobacter fetus can play a role in osteomyelitis, meningitis and joint infection and has a prediliction for the vascular endothelium, causing mycotic aneurysms, thrombophlebitis and endocarditis. Here we present a case of prosthetic valve endocarditis caused by C. fetus and a review of the literature.Case presentationAn 85-year-old woman with a tissue aortic valve replacement and atrial fibrillation was admitted to hospital with tonic-clonic seizures, right-sided hemiparesis, facial droop and hemianopia. Multiple cerebral emboli were seen on magnetic resonance imaging of the brain. Blood cultures grew C. fetus and an echocardiogram showed thickening and restricted movement of the aortic valve, a significant difference from an echocardiogram done 2 months before when the same organism was again isolated in blood cultures. She improved after treatment with 6 weeks of amoxicillin and 2 weeks of synergistic gentamicin for prosthetic valve endocarditis.ConclusionThere have only been five previously reported cases of C. fetus prosthetic valve endocarditis and this is the only patient who presented as a stroke. The majority of surviving patients required replacement of the affected valve with only one other patient surviving in the absence of surgery. No guidelines exist on the optimum treatment of C. fetus endocarditis and this case reports adds to the growing literature on the appropriate management for this rare and potentially devastating disease.

Latent myopathy is more pronounced in patients with low flow versus normal flow aortic stenosis with normal left ventricular ejection fraction who are undergoing surgical aortic valve replacement: Multicenter study with a brief review of the literature.

Midwall fibrosis and low stroke volume are independent predictors of mortality in severe aortic stenosis (AS) with preserved LV ejection fraction (LVEF). The role of speckle tracking echocardiography (STE) to identify latent myopathy pre- and post- aortic valve replacement (AVR) in high risk AS patients with normal LVEF is limited. Demographic, 2D echocardiographic, and STE data were analyzed in patients with severe AS and preserved LVEF who underwent tissue AVR. Velocity vector imaging (VVI) was used to assess regional and global peak systolic longitudinal strain (GLS). Low flow (LF) was defined as an indexed LV stroke volume <35mL/m2 . Between December 2008 and May 2011, 37 patients (75±9years, 51% male) had both pre- and post-AVR echos within 6.6±6.5months (median= 4months; range=2.5-9.5) of surgery. Compared with pre-AVR, GLS (-6.9±4.9% vs -11.1±4.1%; P<.001) and strain rate (-0.72±0.3s-1 vs -0.87±0.3s-1 ; P=.01) improved post-AVR. Pre-AVR mid-segments showed a similar myopathy as the basal segments (-9.5±4.3% vs -9.0±4.2%;P=.3). The 16 (43%) LF patients in this study had lower pre- and post-AVR strain compared to NF patients (GLS Pre-AVR:LF vs NF: -5.1±4.1% vs -8.4±4.9% (P=.04) and GLS Post-AVR:LF vs NF: -9.2±3.7% vs -12.5±3.9% (P=.01)). However, there was no difference in absolute and %change improvement in GLS post-AVR (LF vs NF:∆ -4.2±3.5% vs ∆-4.1±5.3% (P=.90) and 193 ± 214% vs 143 ± 230% change (P=.5)). The lowest GLS was seen in LF/HG AS followed by LF/LG, NF/LG and NF/HG AS; P=.03. Latent myopathy is more pronounced in LF AS both pre- and post-AVR. Our study provides evidence of improvement in myopathy in LF AS despite a persistent worse myopathy compared to NF patients post-AVR.